PT Darya-Varia Laboratoria TbkISX:DVLA 73 EBITDA Margin % is 13.98% as of Mar. 2026, which is 6% above its 10-year median of 13.23. GuruFocus rates ISX:DVLA with a GF Score™ of 73/100 and a GF Value™ of Rp1,840.45 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 952 Drug Manufacturers companies, PT Darya-Varia Laboratoria Tbk ranks worse than 56.2% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
PT Darya-Varia Laboratoria Tbk EBITDA Margin % Related Terms
PT Darya-Varia Laboratoria Tbk EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ISX:DVLA vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PT Darya-Varia Laboratoria Tbk's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Darya-Varia Laboratoria Tbk EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PT Darya-Varia Laboratoria Tbk's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where PT Darya-Varia Laboratoria Tbk's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Darya-Varia Laboratoria Tbk (ISX:DVLA) has a EBITDA Margin % of 13.98% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PT Darya-Varia Laboratoria Tbk and its competitors. This is near median its historical median of 13.23. Over the past decade, PT Darya-Varia Laboratoria Tbk's EBITDA Margin % has ranged from 10.11 to 18.10. According to the industry distribution chart, PT Darya-Varia Laboratoria Tbk ranks #535 out of 952 companies in the Drug Manufacturers industry, placing it in the top 56.2%.
Is PT Darya-Varia Laboratoria Tbk's EBITDA Margin % too high?
PT Darya-Varia Laboratoria Tbk's current EBITDA Margin % of 13.98% is near median its 10-year median of 13.23. Over the past 10 years, this metric has ranged from a low of 10.11 to a high of 18.10. The Drug Manufacturers industry median EBITDA Margin % is 12.47. PT Darya-Varia Laboratoria Tbk's value of 13.98% is 12.1% above this industry median. Based on the distribution chart, PT Darya-Varia Laboratoria Tbk ranks #535 out of 952 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, PT Darya-Varia Laboratoria Tbk has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Darya-Varia Laboratoria Tbk's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PT Darya-Varia Laboratoria Tbk ranks #535 out of 952 companies for EBITDA Margin %. This places PT Darya-Varia Laboratoria Tbk in the lower half of its industry. The industry median EBITDA Margin % is 12.47. PT Darya-Varia Laboratoria Tbk's value of 13.98% is 12.1% above this benchmark. Historically, PT Darya-Varia Laboratoria Tbk's own EBITDA Margin % has ranged from 10.11 to 18.10 over the past decade. While the company's 10-year median is 13.23 vs. the industry median of 12.47, PT Darya-Varia Laboratoria Tbk has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.47, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Darya-Varia Laboratoria Tbk's current EBITDA Margin % of 13.98% is 12.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PT Darya-Varia Laboratoria Tbk and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Darya-Varia Laboratoria Tbk's current EBITDA Margin % is 13.98%, which is near median its own 10-year median of 13.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Darya-Varia Laboratoria Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Darya-Varia Laboratoria Tbk (ISX:DVLA) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp1,840.45, compared to a current price of Rp1,595.00 — trading 13.3% below its estimated fair value. The current EBITDA Margin % is 13.98%, which is near median its 10-year median of 13.23 and 12.1% above the Drug Manufacturers industry median of 12.47. PT Darya-Varia Laboratoria Tbk's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For PT Darya-Varia Laboratoria Tbk (ISX:DVLA), the current EBITDA Margin % is 13.98% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Darya-Varia Laboratoria Tbk (ISX:DVLA) Overvalued in 2026?
Based on GuruFocus' analysis, PT Darya-Varia Laboratoria Tbk stock appears to be undervalued.
The current stock price of Rp1,595.00 is trading 13.3% below its estimated GF Value™ of Rp1,840.45.
GuruFocus considers PT Darya-Varia Laboratoria Tbk to be Modestly Undervalued.
Key valuation signals for ISX:DVLA:
EBITDA Margin %: 13.98% (near median its 10-year median of 13.23)
GF Value™: Rp1,840.45 vs. price of Rp1,595.00 (13.3% below fair value)
Industry Position: 12.1% above the Drug Manufacturers median (#535 of 952)
No single metric tells the full story. See the ISX:DVLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Darya-Varia Laboratoria Tbk Business Description
PT Darya-Varia Laboratoria Tbk (Darya-Varia) is operating in the pharmaceutical industry. It is engaged in the manufacture and trade of pharmaceutical products, human, traditional medicines, pharmaceutical materials, raw materials for traditional medicines, inorganic base chemicals, organic base chemicals, equipment for surgery, medical and dental care, and equipment, orthopedic equipment, prosthetic, eyeglasses, laboratory and health equipment from glass, cosmetics, wholesaler of pharmaceutical, traditional medicine, chemical base materials, laboratory testing services, periodic inspection services, and many more activities. Its business segments include: prescription drugs; consumer health products, which derives key revenue; export and toll manufacturing services; and services.
73GF Score
Get the complete analysis for ISX:DVLA
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:DVLA has been successfully added to your 
